Last updated on October 2018

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

Brief description of study

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Clinical Study Identifier: NCT02576574

Contact Investigators or Research Sites near you

Start Over

Tatsuo Ohira

Tokyo Medical University Hospital
Shinjuku-ku, Japan

Hidehito Horinouchi

National Cancer Center Hospital
Chuo-ku, Japan